CTLA4 and melanoma: In the current study, using estrogen response-related genes that were differentially expressed between ICB responders and non-responders in melanoma, we constructed an 11-gene immunotherapy response prediction signature with stable predictive performance in different melanoma datasets treated with multiple types of immunotherapies (anti-PD-1, anti-CTLA-4 and adoptive T-cell therapy).